Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | DRD3 | P35462 | 4/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.42 |
| ▸ | DRD4 | P21917 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234213 | 0.89 | HTR2A (0.46) | DRD2HTR7HTR2AHTR2CCACNA1B | |
| SCHEMBL3485932 | 0.89 | HTT (0.45) | DRD2HTR7HTR2AHTR2CSMN1; SMN2 | |
| SCHEMBL13541686 | 0.82 | CCR5 (0.43) | DRD2DRD3DRD4ALDH1A1MEN1 | |
| SCHEMBL3485288 | 0.81 | ALDH1A1 (0.53) | DRD2DRD3DRD4ALDH1A1SMN1; SMN2 | |
| SCHEMBL13541685 | 0.80 | DRD4 (0.43) | DRD2DRD3DRD4ALDH1A1MEN1 | |
| SCHEMBL3486050 | 0.79 | CACNA1B (0.50) | DRD2DRD3CACNA1BDRD4ALDH1A1 | |
| SCHEMBL3485714 | 0.79 | DRD4 (0.50) | DRD2DRD3CACNA1BDRD4ALDH1A1 | |
| SCHEMBL3485887 | 0.79 | HTR2A (0.54) | DRD2HTR7HTR2AHTR2CALDH1A1 | |
| SCHEMBL4268462 | 0.78 | CACNA1B (0.49) | CACNA1BSMN1; SMN2NR1I2 | |
| SCHEMBL3485872 | 0.78 | CACNA1B (0.47) | CACNA1BALDH1A1KMT2ASMN1; SMN2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | claimed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | claimed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | claimed |
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | CACNA1A, CACNA1E, CACNA1B | DRD2 264/4885DRD3 273/4885HTR1D 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.